Intramuscular (IM) influenza vaccines are about 50% effective in preventing clinical illness among the elderly and their effectiveness in eliciting mucosal response may be even lower. The aim of the present study was to evaluate the immunological effect of a novel inactivated intranasal (IN) trivale
Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine
✍ Scribed by Akira Ainai; Shin-ichi Tamura; Tadaki Suzuki; Ryo Ito; Hideki Asanuma; Takeshi Tanimoto; Yasuyuki Gomi; Sadao Manabe; Toyokazu Ishikawa; Yoshinobu Okuno; Takato Odagiri; Masato Tashiro; Tetsutaro Sata; Takeshi Kurata; Hideki Hasegawa
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 134 KB
- Volume
- 84
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The levels and properties of neutralizing antibodies in nasal wash and serum collected from five healthy adults were examined after intranasal administration of an A/Uruguay/716/2007 (H3N2) split vaccine (45 µg hemagglutinin (HA) per dose; five doses, with an interval of 3 weeks between each dose). Prior to the assays, nasal wash samples were concentrated so that the total amount of antibodies was equivalent to about 1/10 of that found in the natural nasal mucus. Vaccination induced virus‐specific neutralizing antibody responses, which increased with the number of vaccine doses given. Neutralizing antibodies were produced more efficiently in the nasal passages than in the serum: A ≥4‐fold increase in nasal neutralization titres was observed after the second vaccination in four out of five subjects, whereas a rise in serum neutralization titres was observed only after the fifth vaccination. Nasal and serum neutralizing antibodies were mainly found in the polymeric IgA and monomeric IgG fractions, respectively, after gel filtration. Taken together, these results suggest that intranasal administration of an inactivated split vaccine induces high levels of nasal neutralizing antibodies (primarily polymeric IgA) and low levels of serum neutralizing antibodies (primarily monomeric IgG). J. Med. Virol. 84:336–344, 2012. © 2011 Wiley Periodicals, Inc.
📜 SIMILAR VOLUMES